

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NI *et al.*

Appl. No.: 10/648,825

Filed: August 27, 2003

For: **Death Domain Containing
Receptor-5 Antibodies and
Methods of Use (As Amended)**

Confirmation No.: 3624

Art Unit: 1646

Examiner: KAUFMAN, Claire M.

Atty. Docket: 1488.131000C/EJH/SAC

**Thirteenth Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(d)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08B, is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Thirteenth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Twelfth Information Disclosure Statement filed on April 19, 2007 in connection with the above-captioned application.

A copy of document **AS84** is provided. The Examiner's attention is directed to this document, which is Party Ni's Request for Adverse Judgment to Initiate Review Under 35 U.S.C. § 146 in Patent Interference No. 105,240. The '240 interference involves U.S. Application No. 09/378,045 and U.S. Patent No. 6,872,568, a related patent to the above-captioned application. This document is being cited to fulfill our duty of disclosure under 37 C.F.R. § 1.56.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. The required fee is provided through online credit card payment authorization in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p); in addition:

I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart

foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: October 24, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
737819v1